Cracking KRAS: Can We Finally Treat Pancreatic Cancer?

00:02:02
Dr. Brandon Huffman: Yes. Pancreatic cancer is the third leading cause of cancer-
related death in the United States and is actually thought to become the second leading
cause of cancer-related death by the year of 2030. That’s largely in relation to the stage
at which it presents. So pancreatic cancer, it starts in the pancreas deep in the back of
the abdomen actually, and it can be quiet until it causes problems and it’s more
advanced. So over half of the people with pancreatic cancer when they’re initially
diagnosed have what’s called metastatic disease. That means it is spread beyond the
pancreas to other areas of the body, most commonly the liver, the lungs. It can be along
the lining of the abdomen called the peritoneum. So it can really spread anywhere and
that’s why it’s so aggressive. That’s why it has such a bad rep.

00:03:02
Dr. Kaylee Byers: So it’s not that it affects the most number of people in terms of
cancers. It’s more that for these folks who have pancreatic cancer, by the time we’ve
detected it’s so advanced, treatments are limited.

00:03:15
Dr. Brandon Huffman: That is exactly right. So it is so aggressive and it presents at a
later stage that makes it difficult to treat. We will sometimes use the combination of a
systemic therapy, radiation, and surgery in the earliest stage when it’s just localized to
the pancreas. And that helps people live longer if we can get the cancer out of their
body. But in a majority of cases, we’re not able to do that.

00:03:46
Dr. Kaylee Byers: And what does treatment often look like? You mentioned one, you
could try to get the cancer out of the body, but what are the options that folks have?

00:03:53
Dr. Brandon Huffman: So most commonly, the standard treatment that we have is
systemic chemotherapy. It’s multiple agents of chemo that are given through an IV. So
we use chemotherapy every two weeks. We repeat CT scans every two to three months
and see, is the person with the cancer benefiting from the chemotherapy? And we

determine benefit by the cancer staying the same, no evidence of new cancer, and as
long as they’re tolerating it, then we decide to continue.

00:04:24
Dr. Kaylee Byers: And there’s a whole genetic component to pancreatic cancer. So
when we’re thinking of these genetic variants that might be associated with pancreatic
cancer, what are some of the major ones that we look for?

00:04:36
Dr. Brandon Huffman: Yeah. So KRAS is the most common genetic mutation in
pancreatic adenocarcinoma affecting 90% to 95%. So adenocarcinoma is a cancer that
appears like a gland. And as the pancreas adenocarcinoma develops, it starts as a
normal cell and then acquires genetic mutations over time that then drive cancer cell
proliferation and then causing a tumor to develop a growth of cells that you can then
see on a CT scan or MRI. So as the cancer develops, the earliest event is actually a
KRAS mutation. And then other common genetic mutations are CDKN2A, TP53 and
SMAD4. And there are certainly inherited causes of pancreatic cancer, genes that
you’ve inherited from your parents, BRCA1, BRCA2, PALB2. Those are three relatively
common genetic mutations.

00:05:43
Dr. Kaylee Byers: You might recognize those names. BRCA1 and BRCA2 come up a
lot when we talk about cancer, particularly breast cancer. Morning, Stephanie. How are
you doing?

00:05:55
Stephanie Ramsey: Good morning. I’m all right, thank you. How are you?

00:05:57
Dr. Kaylee Byers: Yeah, good. Meet Stephanie Ramsey.

00:06:00
Stephanie Ramsey: I have been and are currently the director of finance and
operations for Dentons Canada, which is a global law firm. I’m from a very large family.
My father was a concert pianist and a choir director, so there’s a lot of music in our
family. I have kids, I have two kids, I have two grand babies that I just adore. Other than
that, I’m a pancreatic cancer patient right now. It was stage 3. They’re telling me it’s
turning to stage 4, so the journey is ongoing.

00:06:32

Dr. Kaylee Byers: Stephanie is the youngest of eight kids in her family. Her journey
with cancer starts decades ago. Can you tell us about when cancer first became a part
of your life?

00:06:44
Stephanie Ramsey: So my sister was actually the first one diagnosed. She was 39,
and this was in 2000, so this is quite a while ago. So my doctor started testing me the
minute I hit the 39 or 40, and with the first mammogram, identified some abnormalities
and ultimately diagnosed in very early form breast cancer in 2004. So I had
lumpectomy, radiation, bing, bang, boom. Bob’s your uncle, I’m out of there. I’m never
doing this again, was basically how I thought about it. Went for 15 years, totally disease-
free, and then it reared its ugly head again with a more serious diagnosis on the same
side. By the time that hit, my mother had been diagnosed two years prior with breast
cancer when she was 80, and then my oldest sister was diagnosed when she was 64,
65, just before I was with my second one. She’s in the United States. So in the United
States, they habitually do genetic testing as a matter of course, and they discovered
that she had the BRCA2 gene. So when I told this to my oncologist, she said, “Well, you
should be tested.” And I said, “Well, why?” She said, “Because if you have it, it puts you
at a 35% to 40% chance of other cancers.” I said, “Okay, where do I sign?” And off we
went into the journey. And so of course came back with a positive BRCA2 mutation and
advised everyone in my family, obviously we have this issue and people need to start
going to get tested. So out of eight kids, six have been proven to have the BRCA2 gene.
Once we identified that genetic mutation, everything changed. Everything changed for
me, everything changed for my whole family.

00:08:39
Dr. Kaylee Byers: Because other members of Stephanie’s family had tested positive for
a BRCA2 variant, Stephanie knew she could be at a higher risk for certain cancers too.
So she had more frequent testing to keep an eye out for signs.

00:08:51
Stephanie Ramsey: My family physician was testing my blood on a regular basis
because of anomalies, and then all of a sudden they went crazy in 2023. So 2019 was
the second breast cancer, and then 2023 was the diagnosis for pancreatic cancer,
which just came completely out of the blue and literally kicked me in the gut.

00:09:11
Dr. Kaylee Byers: Yeah. It must have been extremely shocking.

00:09:15

Stephanie Ramsey: It was.

00:09:15
Dr. Kaylee Byers: And I also wonder, do you feel like they would’ve caught it if you
hadn’t already been keeping on track of your other diagnosis through blood work?

00:09:23
Stephanie Ramsey: No, I don’t. I actually, I hug my physician every time I see her
because she’ll call herself extremely type A and anal. I will call her my savior because I
was feeling okay. I didn’t feel horribly sick. I didn’t have horrible symptoms of pain or
abdominal discomfort. See, this is the thing about pancreatic cancer, these symptoms
are different for everyone. So I credit her and those tests for finding it.

00:09:55
Dr. Kaylee Byers: Well, and especially with pancreatic cancer, often folks don’t realize
until it’s too late. I lost a family member to pancreatic cancer and by the time the
diagnosis came, they were gone within a month. I think it was two or three weeks. It
wasn’t long.

00:10:08
Stephanie Ramsey: Yeah, and I think that’s kind of a typical story, unfortunately. I
consider myself extremely blessed because of where I am now, even though I’m facing
what I’m facing, I’ve gotten three full years since that diagnosis, and that makes me
absolutely ecstatic. I’m not quite a unicorn, but I’m getting there. That’s what we call
people who get to five years.

00:10:33
Dr. Kaylee Byers: I think that’s a great… Why unicorn? Is it because they’re mythical?

00:10:37
Stephanie Ramsey: Exactly. I think mythical is a good word to use, yeah, because it’s
so uncommon. So it’s pretty impressive when you get there.

00:10:44
Dr. Kaylee Byers: It is. Yeah. And so you’ve already gotten used to this, okay, I’m
dealing with breast cancer and now I have this other diagnosis. What was that
experience and that part of the journey like for you?

00:10:56

Stephanie Ramsey: That was really wild. It’s so hard to describe the feeling that I had
when I had been through so much already and to now have this one, which was so
different and so much worse. I mean, trying to tell my kids was the hardest thing I’ve
ever done. My kids are grown, they’re adults. They understand these things. But I mean,
to tell your kids that you have this life-limiting illness, that was very difficult to deal with.
But I was very fortunate to be in Ottawa because we have an outstanding cancer
center, so I had every confidence in all of the people who were treating me, and that
helped to make things better. You’re just in a fog and you go through this because you
have to, you do what they tell you is the thing to do, and you really don’t know anything
because it’s overwhelming.

00:11:48
Dr. Kaylee Byers: Yeah. What has treatment looked like for you?

00:11:52
Stephanie Ramsey: So treatment for pancreatic cancer is limited. When you have
breast cancer, there’s a number of different cocktail drugs that they use. There are
different techniques in radiation technology, even radiation therapy. So if you’re not
responding well to a given cocktail or a given drug, they can pivot and find something
else that’s helpful. With pancreatic cancer, there’s really two options. So it’s very limited
because there’s just too much they don’t know and they’ve had such a hard time nailing
down how do we try to identify it early and how do we stop it from moving and growing
the way it does? It’s, according to everything I’ve read, one of the most complex cancers
for them to deal with.

00:12:38
Dr. Kaylee Byers: Part of the reason treatment for this disease has been so slim
pickings goes back to the genetics. Dr. Huffman explained earlier that mutations in the
KRAS gene are the most common genetic drivers of pancreatic cancer, and it’s kind of
the MVG of our episode today. For decades, KRAS was considered undruggable until a
very KRAS-y discovery in 2013.

00:13:04
Dr. Brandon Huffman: So 2013, there’s a scientist, Kevan Shokat, found this pocket on
the kind of inactive side of KRAS called the switch-II binding pocket.

00:13:16
Dr. Kaylee Byers: And this itty bitty pocket turned out to be a huge deal. To understand
why though, we have to look at how KRAS works.

00:13:26
Dr. Brandon Huffman: You have to think of the function of KRAS, right? It has
essentially two forms. It’s like a molecular switch where when it’s on, when it’s GTP-
bound, it’s causing cell growth. And when it’s GDP-bound, then it’s kind of off.

00:13:44
Dr. Kaylee Byers: Okay. GTP on, GDP off. You see, the KRAS gene contains the
instructions for making a protein and helps control cell growth. Think of the protein like a
light switch. Normally, it flips on and off to tell cells when to grow, but cancer-causing
mutations can leave the protein stuck in the on position, so cells keep growing when
they shouldn’t. And for years, scientists couldn’t locate a spot in the protein for a drug to
latch onto and turn it off. It’s like knowing you need to flip a light switch, but just not
being able to reach it.

00:14:22
Dr. Brandon Huffman: That’s kind of the biggest reason that we’ve understood that it
was undruggable. And so Dr. Shokat and his lab discovered that the switch to binding
pocket could keep the KRAS protein in the off position, essentially, GDP-bound.

00:14:41
Dr. Kaylee Byers: So suddenly, with the discovery of this little old pocket, scientists
had to weigh in and could turn KRAS off. This became a major proof of concept for a
new class of drugs called KRAS inhibitors.

00:14:56
Dr. Brandon Huffman: This is the discovery of the century. And then fast-forward, we
have other KRAS inhibitors that are in clinic that have proven to be profoundly
efficacious, not cures for patients, but definitely helping them live longer and better lives,
and that’s one of our main goals.

00:15:17
Dr. Kaylee Byers: Coming up, a hot new drug is beaming in.

00:15:20
Clip: Energize.

00:15:21
Dr. Brandon Huffman: What it showed was it nearly doubled overall survival compared
to just receiving chemotherapy.

00:15:29
Dr. Kaylee Byers: Don’t go anywhere. You are listening to Nice Genes, a podcast all
about the fascinating world of genomics and the evolving science behind it, brought to
you by Genome British Columbia. I’m your host, Dr. Kaylee Byers, and we want to get
more people to listen to the genomic stories that are shaping our world. So if you like
Nice Genes, hit follow on Apple Podcasts or wherever you get your shows. If this
episode has you excited about all the latest and greatest in genomics, help us kick even
more pancreas by sharing this episode with a friend and leaving us a review. 2026 was
a landmark year for pancreatic cancer treatment.

00:16:09
Clip: It’s being called a turning point in the fight against pancreatic cancer.

00:16:13
Clip: Just a few hours ago, the FDA approved a groundbreaking drug for the most
aggressive form of this cancer.

00:16:19
Clip: A new study shows the pill taken daily doubled survival time with daraxonrasib.

00:16:25
Dr. Kaylee Byers: A new drug called daraxonrasib recently became FDA approved and
got a lot of attention. So let’s get into it. What exactly is daraxonrasib and why is it such
a big deal? Is this new drug, which I always struggle to say, daraxonrasib?
Daraxonrasib? Did I do it?

00:16:44
Dr. Brandon Huffman: Whoa, nice. Yes, you got it.

00:16:49
Dr. Kaylee Byers: Thank you so much. So what is this drug actually doing inside a
cancer cell?

00:16:56
Dr. Brandon Huffman: Yeah, so I said that the discovery of the century was targeting
the switch-II binding pocket. Actually, this is a totally different mechanism of action. So
what daraxonrasib is, is a really unique molecule and what it does is it binds GTP-bound
KRAS and shrinks the tumor, causes decreased cell proliferation, and that in patients
has now been studied in phase 1, phase 2, and phase 3 randomized clinical trials and
have proven that when it is used as an alternative to chemotherapy, it helps people live

longer and better lives. So it’s a pill you take once per day. And just to kind of give a
better picture, so clinical trials, phase 1 is we’re trying to understand can we get to a
dose that is safe but also has activity against the target. In this case, the target is RAS.
Then they saw in the phase 2, which is where they have a safe dose and we think that
it’s efficacious, but we want to study it in a larger population, and that was published in
the New England Journal of Medicine and shows an excellent response rate that the
cancer shrinks more than 30% and there’s no new development of cancer. That led to
the randomized phase 3 clinical trial where we’re trying to answer the statistical
question, does daraxonrasib improve overall survival and progression-free survival in
patients as an alternative to the standard of care chemotherapy? And what it showed
was it nearly doubled overall survival compared to just receiving chemotherapy. Now,
that is a major proof of concept that we can use a drug, just a pill alone, and it helps
control the cancer long enough that it helps people live longer than the old standard of
care.

00:19:00
Dr. Kaylee Byers: Daraxonrasib isn’t a cure, but it is helping patients with pancreatic
cancer live longer. And for Dr. Huffman, it’s more than just one new medication. It’s the
start of a major shift.

00:19:14
Dr. Brandon Huffman: Daraxonrasib RAS inhibition in general is a paradigm shift for
the treatment of pancreatic cancer because what we’re now seeing is that we can target
the driver and potentially we can combine that with other novel therapies to overcome
the resistance that might develop either initially or later on. And that ultimately will
become the backbone of our treatments. And if we can target the driver of the cancer,
patients live longer, and that is what I’m really excited about.

00:19:47
Dr. Kaylee Byers: So what about patients like Stephanie whose cancer is driven by a
different mutation like BRCA2? Is daraxonrasib an option for them?

00:19:59
Dr. Brandon Huffman: BRCA1 and BRCA2, PALB2, they’re actually co-occurrent with
KRAS in many cases. So just because someone has a BRCA1 or BRCA2-driven cancer
doesn’t mean that they don’t also have a cancer that has a KRAS mutation. In fact, up
to 95% of pancreatic adenocarcinomas have a KRAS mutation.

00:20:23

Dr. Kaylee Byers: Yeah, so actually if you have some of these other mutations, you
might also have a KRAS mutation. So having that kind of genetic testing for multiple
types of mutations is helpful to know.

00:20:33
Dr. Brandon Huffman: Oh my gosh. So that is such an incredibly important point.
Every person with pancreatic adenocarcinoma should have genetic testing of their
cancer, full stop. It just has to happen because in particular, if the cancer doesn’t have a
KRAS mutation, there’s potentially another driver. I mean, these are less than 1% of the
people with pancreatic cancers, so they’re needles in haystacks, but when you have the
cancer that has the needle, you want a therapy that’s potentially going to change the
trajectory of your life, and there’s a new novel therapy alternative to daraxonrasib, and
it’s also a pill targeted therapy.

00:21:14
Dr. Kaylee Byers: This is important to highlight. We’re focusing on one hot new drug
here, but there’s a lot more happening with pancreatic cancer treatment right now, from
personalized and targeted therapies, to mRNA vaccines, to AI tools that could help
detect tumors earlier. And the more we understand the genetic drivers of someone’s
cancer, the better we can match them with the right treatment. So there’s a lot of moving
parts, and for people like Stephanie who are living with a pancreatic cancer diagnosis,
the treatment landscape looks very different than it did even a few years ago. So
Stephanie, when you hear about things like daraxonrasib, what’s it mean to you? How
does it make you feel?

00:21:55
Stephanie Ramsey: It’s a game changer. It’s an absolute game changer, and the
elation, when we see these articles come out and we see the reaction to it in some of
the research that we’re reading, it lifts you completely. And I say that at this stage
because I’m facing a stage 4 progression. I’ve had this conversation with my oncologist
already to see if it is something that I will be able to consider. So they’re testing me right
now to see if I will be eligible, but we’ll see.

00:22:26
Dr. Kaylee Byers: But while this is a groundbreaking treatment, there are inevitably
some holdups. daraxonrasib was only FDA approved in August of this year, so it’s just
becoming available to patients in the United States. So what’s that mean for patients
here in Canada, and what other barriers might stand in the way for the people who can
access it?

00:22:46
Stephanie Ramsey: It’s difficult because it’s such a small subset of the population who
gets pancreatic cancer. Research is usually done on things like breast cancer, like
colorectal cancer, where larger subsets of the population are affected because that’s
where big pharma is going to make their money. I mean, daraxonrasib is said to be
something like $ 60,000 a month.

00:23:14
Dr. Kaylee Byers: That’s the estimate in Canadian dollars, just BTW.

00:23:17
Stephanie Ramsey: So this might not even be a treatment that everyone is going to be
able to access. I hope it will be. It’s been approved in the United States finally, but the
United States also has a mechanism of approval of these things that we don’t have, and
that is they have an emergency use component, which allows them to introduce the
drug to people who have no other options if they’re willing to take the chance. So they
don’t even have right now the ability to approve it for any use at all. They have nothing
right now. They’re nowhere in the picture. That concerns me greatly. We take too long
to get these new treatments accessible to our people here.

00:24:00
Dr. Kaylee Byers: For patients, new medicines can be a very weird kind of good news.
You can have a promising new drug, you can know it works, and you can still be waiting
for it to actually reach the people who need it. And when you’re living with an aggressive
cancer, waiting isn’t really an option. That’s where community comes in, because while
researchers work on treatments, patients, advocates, and organizations are telling the
system…

00:24:29
Clip: You better work.

00:24:31
Dr. Kaylee Byers: So I know you’re part of a nonprofit organization here in Canada
called Craig’s Cause. Can you tell us a little bit about Craig’s Cause and what it does?

00:24:39
Stephanie Ramsey: So Craig’s Cause was created by a woman whose father passed
very quickly, diagnosed and gone within weeks. And she said, “Yeah, this isn’t
acceptable and I’m going to use his legacy to build this charitable organization.” So
Craig’s Cause does everything from educating patients and public abroad about

pancreatic cancer. They stay on top of clinical trials. They have tools for us to use as
patients, as families, as caregivers within the pancreatic cancer community. They help
with financial considerations from time to time for different things. It’s a total package in
terms of helping the community affected with pancreatic cancer. They are huge
advocates in terms of getting out there and telling the stories and bringing awareness to
this disease and to how difficult it is for people to deal with and new things that could be
coming down the pipe, lobbying with government to try and get more funding, more
research, more everything. So they’re a small organization, but boy, they certainly have
a reach. I joined their advocacy team because I felt, you know what, this could really do
a lot of good and they’re special to me obviously.

00:26:04
Dr. Kaylee Byers: I know this is big news that Craig’s Cause is launching its first
national study looking at gaps in care in relation to pancreatic cancer. So based off your
own experience and the community, what are some of the ones you think that we really
need to tackle? What are some of those big gaps in care?

00:26:22
Stephanie Ramsey: Well, one of the things that I believe is a primary gap is regional
because of the way our system works and sizes of cities and sizes of medical centers.
When I’m diagnosed with pancreatic cancer in Ottawa, I have the hepatobiliary expert
team to look after my surgical care. If you’re in Newfoundland, do you have the same
access that someone in the Ottawa area would? I would venture to guess that the
answer to that is no. So that I think is primary. I think there’s the regional component. I
think there’s gaps in our funding based on our provincial model and how our dollars are
spent and just inconsistencies, I guess, throughout Canada. With a disease of this
nature, it’s also very difficult for governments to spend money on trying to save a very
small subset of the population, and that’s just a reality of Canadian healthcare, I think.
That sounds really bad and I don’t want it to sound bad.

00:27:28
Dr. Kaylee Byers: I know. We know why it is. We know why it is, but it’s still really
frustrating if only we had endless money.

00:27:39
Stephanie Ramsey: Well, exactly, and we don’t. And that being said, the majority of our
people are able to get exceptional care for all kinds of diseases and illnesses, and that’s
the good side of socialized medicine, obviously. The other big gaps is early detection.
It’s almost impossible to detect pancreatic cancer early.

00:28:04
Dr. Kaylee Byers: Stephanie, you’ve obviously been through a lot and you continue to
go through a lot, and I’m really sorry to hear about the stage 4-

00:28:13
Stephanie Ramsey: Oh, thank you.

00:28:13
Dr. Kaylee Byers: … diagnosis. But you also still spend a lot of your time contributing to
Craig’s Cause. What is it about that? Why put your energy there during this time?

00:28:26
Stephanie Ramsey: I guess part of what made me who I am was being able to effect
change within my career, within my personal life, or be a positive person in somebody’s
life who may have very little to be positive about. It gives me an opportunity to do
something good with all of this mess. It’s really easy to get buried with the darkness of a
cancer diagnosis of any kind, let alone one that is life-threatening and life limiting. But
the people that I have met because of it is an absolute treasure to me. Obviously, when
you’re faced with this stuff, you kind of get very spiritual about things as well. I went on a
healing journey to the West Coast, and I felt completely different when I came back from
that, and it made me want to do exactly that, to spend whatever time I have left. And I
kind of made myself a plan. If I was going to live for two years, then that would be a
great success to me. And for those two years, if I felt well enough, I want to do these
things. I did those things, and that’s like, boom, that’s awesome. Then if I get past that,
then I’m going to have to revisit my finances, but-

00:29:58
Dr. Kaylee Byers: Yeah.

00:29:58
Stephanie Ramsey: … that’s okay too. So it’s part of what keeps me going. Helping
and being able to use my voice, my experiences, my personal situation to help
someone else or to inform people who are learning more and more about the genetic
components and everything else. I think that’s awesome. I think that gives me joy.

00:30:31
Dr. Kaylee Byers: What is another thing that’s on your list of things you want to do?
Finances, be damned.

00:30:36

Stephanie Ramsey: Well, let’s see. I would love to go to Iceland. Iceland would be
really cool. I did the Alaska Cruise, which was one of my bucket list items. I did the
Cross Canada train, which was spectacular. There’s a lot of stuff. The other thing is I’d
like to do it with my kids and my grandkids. One of the things that my son said to me
recently, which it might change how I do things, is he said to me, “Mom, if your time now
is going to be even more limited, if you’re going somewhere, I have to go with you.” And
I get it. I get it. I totally understand what he’s saying. And that really hit me in the heart.
So you know what? Maybe I need to just stay closer to home. Maybe that’s where I’m
meant to be so that I can be with my family. And I think from everything I’ve learned
through Craig’s Cause and experiencing all of that with the people who are living and
dying together, it’s given me so many gifts. And I consider all of this to be a gift because
most people take for granted the time that they have. And I won’t do that. I can’t do that.
So that’s a good thing. And it gives you a lot of oomph.

00:31:59
Dr. Kaylee Byers: You definitely seem like you have oomph and spades, Stephanie.

00:32:01
Stephanie Ramsey: Oomph and spades.

00:32:06
Dr. Kaylee Byers: Stephanie, I’m really glad to have met you. Thank you for taking
some of your time in a very tumultuous time to talk with us about your experience. And I
wish you unicorn status and beyond.

00:32:21
Stephanie Ramsey: Thank you. I really appreciate this and this has been very
enjoyable, so thank you.

00:32:27
Dr. Kaylee Byers: For a cancer that was once considered undruggable, we are
entering a whole new era of treatment and genomics is helping lead the way, but a
breakthrough only really matters if it reaches the people who need it. Science can open
new doors, but now we need to make sure that patients have a chance to walk through
them so we can imagine a world where unicorns aren’t so mythical. Our guests for today
were medical oncologist in the Gastrointestinal Cancer Center of Dana-Farber Cancer
Institute and faculty member at Harvard Medical School, Dr. Brandon Huffman, and
cancer patient, advocate, and true treasure, Stephanie Ramsey. You’ve been listening
to Nice Genes, a podcast brought to you by Genome British Columbia. If you liked this
episode, go check out some of our previous ones wherever you listen from. Share us

with your friends and leave us a review. You can also DM the show on social media by
going to @GenomeBC. Next time, get your capes ready. We are on a mission to learn
what makes super-agers super and what they can teach us about longevity.

00:33:35
Dr. Angela Roberts: They age unlike any other group. These are 80-and 90-year-olds
who have extraordinary cognitive function.

00:33:42
Dr. Kaylee Byers: As always, thanks so much for listening. GDP, off.